Business Context and Reporting Period
This Form 8-K filing by Propanc Biopharma, Inc. (PPCB) reports corporate governance changes effective July 8, 2026. The company is incorporated in Delaware and maintains its principal executive office in Camberwell, Australia. The filing was signed on July 14, 2026, by James Nathanielsz, who serves as both Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Departure: Annie Van Broekhoven retired and stepped down from the Board of Directors effective July 8, 2026.
- Director Appointment: The Board appointed Carlo Campiciano to fill the vacancy created by Ms. Van Broekhoven's resignation.
Outlook, Risks, and Management Commentary
The filing details the qualifications of the new director, Carlo Campiciano, highlighting his background as a qualified accountant with US GAAP certification and extensive experience in finance, taxation, and capital raising. Mr. Campiciano previously served as CFO and Company Secretary for MedAdvisor Limited (ASX-listed) and has experience in venture finance. No specific guidance, risks, or unusual items regarding the company's operational outlook were disclosed in this document.
Investor Verification Checklist
- Verify the terms of the Director Agreement (Exhibit 10.1) between Propanc Biopharma and Carlo Campiciano.
- Confirm the current composition of the Board of Directors following the transition.
- Review the company's most recent 10-K or 10-Q filings for financial data, as this 8-K contains none.